{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:21:45Z","timestamp":1784064105553,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,21]]},"DOI":"10.7759\/cureus.99752","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T09:12:04Z","timestamp":1766308324000},"source":"Crossref","is-referenced-by-count":1,"title":["Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Lipid Modulation in Heart Failure: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Sina","family":"Neshat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazhir","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matin","family":"Bidares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Falahati Marvast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronal","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyan","family":"Heshmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn153","article-title":"Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme","volume":"29","author":"MacDonald MR","year":"2008","unstructured":"MacDonald MR, Petrie MC, Varyani F, et al.. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008, 29:1377-85. 10.1093\/eurheartj\/ehn153","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3525-8","article-title":"Pathophysiology of diabetic dyslipidaemia: where are we?","volume":"58","author":"Verg\u00e8s B","year":"2015","unstructured":"Verg\u00e8s B. Pathophysiology of diabetic dyslipidaemia: where are we?. Diabetologia. 2015, 58:886-99. 10.1007\/s00125-015-3525-8","journal-title":"Diabetologia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021, 385:1451-61. 10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon SD","year":"2022","unstructured":"Solomon SD, McMurray JJ, Claggett B, et al.. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022, 387:1089-98. 10.1056\/NEJMoa2206286","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030723","article-title":"Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach","volume":"89","author":"Bays H","year":"2004","unstructured":"Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004, 89:463-78. 10.1210\/jc.2003-030723","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \"thrifty substrate\" hypothesis","volume":"39","author":"Ferrannini E","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a \"thrifty substrate\" hypothesis. Diabetes Care. 2016, 39:1108-14. 10.2337\/dc16-0330","journal-title":"Diabetes Care"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115005","article-title":"Role of free fatty acids and insulin in determining free fatty acid and lipid oxidation in man","volume":"87","author":"Groop LC","year":"1991","unstructured":"Groop LC, Bonadonna RC, Shank M, Petrides AS, DeFronzo RA. Role of free fatty acids and insulin in determining free fatty acid and lipid oxidation in man. J Clin Invest. 1991, 87:83-9. 10.1172\/JCI115005","journal-title":"J Clin Invest"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? a unifying hypothesis","volume":"39","author":"Mudaliar S","year":"2016","unstructured":"Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? a unifying hypothesis. Diabetes Care. 2016, 39:1115-22. 10.2337\/dc16-0542","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-016-0491-5","article-title":"Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin","volume":"16","author":"Hayashi T","year":"2017","unstructured":"Hayashi T, Fukui T, Nakanishi N, et al.. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017, 16:8. 10.1186\/s12933-016-0491-5","journal-title":"Cardiovasc Diabetol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12307","article-title":"Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis","volume":"16","author":"Liakos A","year":"2014","unstructured":"Liakos A, Karagiannis T, Athanasiadou E, et al.. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014, 16:984-93. 10.1111\/dom.12307","journal-title":"Diabetes Obes Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007165","article-title":"Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis","volume":"7","author":"Zhang XL","year":"2018","unstructured":"Zhang XL, Zhu QQ, Chen YH, Li XL, Chen F, Huang JA, Xu B. Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis. J Am Heart Assoc. 2018, 7:10.1161\/JAHA.117.007165","journal-title":"J Am Heart Assoc"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2018.1541348","article-title":"SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids","volume":"14","author":"Filippas-Ntekouan S","year":"2018","unstructured":"Filippas-Ntekouan S, Tsimihodimos V, Filippatos T, Dimitriou T, Elisaf M. SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. Expert Opin Drug Metab Toxicol. 2018, 14:1113-21. 10.1080\/17425255.2018.1541348","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2022.100176","article-title":"The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic \u03b2-oxidation, and induces ketosis","volume":"63","author":"Wallenius K","year":"2022","unstructured":"Wallenius K, Kroon T, Hagstedt T, et al.. The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic \u03b2-oxidation, and induces ketosis. J Lipid Res. 2022, 63:100176. 10.1016\/j.jlr.2022.100176","journal-title":"J Lipid Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2337\/db16-0049","article-title":"Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism","volume":"65","author":"Briand F","year":"2016","unstructured":"Briand F, Mayoux E, Brousseau E, et al.. Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes. 2016, 65:2032-8. 10.2337\/db16-0049","journal-title":"Diabetes"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal B","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al.. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017, 377:644-57. 10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-4946-6","article-title":"55(th) EASD annual meeting of the European Association for the Study of Diabetes: Barcelona, Spain, 16 - 20 September 2019","volume":"62","year":"2019","unstructured":"55(th) EASD annual meeting of the European Association for the Study of Diabetes. Barcelona, Spain, 16 - 20 September 2019. Diabetologia. 2019, 62:1-600. 10.1007\/s00125-019-4946-6","journal-title":"Diabetologia"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0041","article-title":"SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study","volume":"39","author":"Abdul-Ghani M","year":"2016","unstructured":"Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 2016, 39:717-25. 10.2337\/dc16-0041","journal-title":"Diabetes Care"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-017-6724-3","article-title":"The effect of sodium-glucose co-transporter-2 (SGLT-2) inhibitors on cardiometabolic profile; beyond the hypoglycaemic action","volume":"31","author":"Lioudaki E","year":"2017","unstructured":"Lioudaki E, Androulakis ES, Whyte M, Stylianou KG, Daphnis EK, Ganotakis ES. The effect of sodium-glucose co-transporter-2 (SGLT-2) inhibitors on cardiometabolic profile; beyond the hypoglycaemic action. Cardiovasc Drugs Ther. 2017, 31:215-25. 10.1007\/s10557-017-6724-3","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.33070","article-title":"Assessment of the safety, efficacy, and benefit of empagliflozin in patients with type 2 diabetes mellitus (T2 DM) and heart failure with reduced ejection fraction (HFrEF) at high risk for cardiovascular events","volume":"14","author":"Towiargi R","year":"2022","unstructured":"Towiargi R, Fetyani L, Aljahdali N, et al.. Assessment of the safety, efficacy, and benefit of empagliflozin in patients with type 2 diabetes mellitus (T2 DM) and heart failure with reduced ejection fraction (HFrEF) at high risk for cardiovascular events. Cureus. 2022, 14:e33070. 10.7759\/cureus.33070","journal-title":"Cureus"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0914-1","article-title":"Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction","volume":"18","author":"Zhang N","year":"2019","unstructured":"Zhang N, Feng B, Ma X, Sun K, Xu G, Zhou Y. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Cardiovasc Diabetol. 2019, 18:107. 10.1186\/s12933-019-0914-1","journal-title":"Cardiovasc Diabetol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106667","article-title":"Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: from clinical evidence to molecular mechanisms","volume":"188","author":"Osto E","year":"2023","unstructured":"Osto E, Bonacina F, Pirillo A, Norata GD. Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: from clinical evidence to molecular mechanisms. Pharmacol Res. 2023, 188:106667. 10.1016\/j.phrs.2023.106667","journal-title":"Pharmacol Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13903","article-title":"Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study","volume":"85","author":"Phrommintikul A","year":"2019","unstructured":"Phrommintikul A, Wongcharoen W, Kumfu S, Jaiwongkam T, Gunaparn S, Chattipakorn S, Chattipakorn N. Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study. Br J Clin Pharmacol. 2019, 85:1337-47. 10.1111\/bcp.13903","journal-title":"Br J Clin Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeaa356.021","article-title":"Impact of dapagliflozin on left ventricular diastolic function in diabetic patients with heart failure complicating cardiovascular risk factors","volume":"22","author":"Soga F","year":"2021","unstructured":"Soga F, Tanaka H, Tatsumi K, et al.. Impact of dapagliflozin on left ventricular diastolic function in diabetic patients with heart failure complicating cardiovascular risk factors. Eur Heart J Cardiovasc Imaging. 2021, 22:27. 10.1093\/ehjci\/jeaa356.021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000912984.49909.25","article-title":"S-09-5: epidemiology and cardiometabolic disorders - update of SGKT2-is RCT meta-analysis","volume":"41","author":"Yang X","year":"2023","unstructured":"Yang X, Cao Y, Yan C, Zhang Y, Dong Y, Feng Y. S-09-5: epidemiology and cardiometabolic disorders - update of SGKT2-is RCT meta-analysis. J Hypertension. 2023, 41:30. 10.1097\/01.hjh.0000912984.49909.25","journal-title":"J Hypertension"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci A","year":"2014","unstructured":"Merovci A, Solis-Herrera C, Daniele G, et al.. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014, 124:509-14. 10.1172\/JCI70704","journal-title":"J Clin Invest"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001083","article-title":"Effect of canagliflozin compared with sitagliptin on serum lipids in patients with type 2 diabetes mellitus and heart failure with reduced ejection fraction: a post-hoc analysis of the CANA-HF study","volume":"78","author":"Dixon DL","year":"2021","unstructured":"Dixon DL, Billingsley HE, Canada JM, et al.. Effect of canagliflozin compared with sitagliptin on serum lipids in patients with type 2 diabetes mellitus and heart failure with reduced ejection fraction: a post-hoc analysis of the CANA-HF study. J Cardiovasc Pharmacol. 2021, 78:407-10. 10.1097\/FJC.0000000000001083","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0877-2","article-title":"Canagliflozin for Japanese patients with chronic heart failure and type II diabetes","volume":"18","author":"Sezai A","year":"2019","unstructured":"Sezai A, Sekino H, Unosawa S, Taoka M, Osaka S, Tanaka M. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes. Cardiovasc Diabetol. 2019, 18:76. 10.1186\/s12933-019-0877-2","journal-title":"Cardiovasc Diabetol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.01.025","article-title":"Sodium-glucose cotransporter 2 inhibitors in tafamidis-treated transthyretin amyloid cardiomyopathy: a contemporary real-world analysis","volume":"13","author":"Chi KY","year":"2025","unstructured":"Chi KY, Varrias D, Borkowski P, et al.. Sodium-glucose cotransporter 2 inhibitors in tafamidis-treated transthyretin amyloid cardiomyopathy: a contemporary real-world analysis. JACC Heart Fail. 2025, 13:863-6. 10.1016\/j.jchf.2025.01.025","journal-title":"JACC Heart Fail"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32590-x","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker TA","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al.. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019, 393:31-9. 10.1016\/s0140-6736(18)32590-x","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-085081","article-title":"Demographic and clinical characteristics of New York City Health + Hospitals HIV Heart Failure (NYC4H cohort): cohort profile","volume":"14","author":"Chen YY","year":"2024","unstructured":"Chen YY, Borkowski P, Nazarenko N, et al.. Demographic and clinical characteristics of New York City Health + Hospitals HIV Heart Failure (NYC4H cohort): cohort profile. BMJ Open. 2024, 14:e085081. 10.1136\/bmjopen-2024-085081","journal-title":"BMJ Open"},{"key":"ref34","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehx493.P4903","article-title":"Empagliflozin reduces heart failure irrespective of control of blood pressure, low density lipoprotein cholesterol and HbA1c","volume":"38","author":"Fitchett D","year":"2017","unstructured":"Fitchett D, McKnight J, Lee J, George J, Mattheus M, Woerle HJ, Inzucchi SE. Empagliflozin reduces heart failure irrespective of control of blood pressure, low density lipoprotein cholesterol and HbA1c. Eur Heart J. 2017, 38:1029.","journal-title":"Eur Heart J"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012325","article-title":"Repurposing SGLT-2 inhibitors to target aging: available evidence and molecular mechanisms","volume":"23","author":"La Grotta R","year":"2022","unstructured":"La Grotta R, Frig\u00e9 C, Matacchione G, Olivieri F, de Candia P, Ceriello A, Prattichizzo F. Repurposing SGLT-2 inhibitors to target aging: available evidence and molecular mechanisms. Int J Mol Sci. 2022, 23:10.3390\/ijms232012325","journal-title":"Int J Mol Sci"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2014.20","article-title":"Tofogliflozin, a sodium\/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models","volume":"4","author":"Suzuki M","year":"2014","unstructured":"Suzuki M, Takeda M, Kito A, et al.. Tofogliflozin, a sodium\/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes. 2014, 4:e125. 10.1038\/nutd.2014.20","journal-title":"Nutr Diabetes"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2018.08.016","article-title":"Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)","volume":"206","author":"Cannon CP","year":"2018","unstructured":"Cannon CP, McGuire DK, Pratley R, et al.. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J. 2018, 206:11-23. 10.1016\/j.ahj.2018.08.016","journal-title":"Am Heart J"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14017","article-title":"Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?","volume":"22","author":"Coleman RL","year":"2020","unstructured":"Coleman RL, Gray AM, Broedl Md UC, et al.. Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?. Diabetes Obes Metab. 2020, 22:1151-6. 10.1111\/dom.14017","journal-title":"Diabetes Obes Metab"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13615","article-title":"Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial","volume":"8","author":"Fitchett D","year":"2021","unstructured":"Fitchett D, Inzucchi SE, Zinman B, et al.. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. ESC Heart Fail. 2021, 8:4517-27. 10.1002\/ehf2.13615","journal-title":"ESC Heart Fail"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2019.12.071","article-title":"Consistent cardiovascular (CV) benefit of empagliflozin over the spectrum of CV risk factor control in EMPA-REG OUTCOME","volume":"104","author":"Inzucchi SE","year":"2020","unstructured":"Inzucchi SE, Khunti K, Fitchett DH, et al.. Consistent cardiovascular (CV) benefit of empagliflozin over the spectrum of CV risk factor control in EMPA-REG OUTCOME. Metabol Clin Experiment. 2020, 104:154125. 10.1016\/j.metabol.2019.12.071","journal-title":"Metabol Clin Experiment"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.04.040","article-title":"Are the favorable cardiovascular outcomes of empagliflozin treatment explained by its effects on multiple cardiometabolic risk factors? A simulation of the results of the EMPA-REG OUTCOME trial","volume":"141","author":"Kuo S","year":"2018","unstructured":"Kuo S, Ye W, Duong J, Herman WH. Are the favorable cardiovascular outcomes of empagliflozin treatment explained by its effects on multiple cardiometabolic risk factors? A simulation of the results of the EMPA-REG OUTCOME trial. Diabetes Res Clin Pract. 2018, 141:181-9. 10.1016\/j.diabres.2018.04.040","journal-title":"Diabetes Res Clin Pract"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.069217","article-title":"Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: insights from the EMPACT-MI trial","volume":"149","author":"Hernandez AF","year":"2024","unstructured":"Hernandez AF, Udell JA, Jones WS, et al.. Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: insights from the EMPACT-MI trial. Circulation. 2024, 149:1627-38. 10.1161\/CIRCULATIONAHA.124.069217","journal-title":"Circulation"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-024-01438-1","article-title":"Impact of canagliflozin combined with metformin therapy on reducing cardiovascular risk in type 2 diabetes patients","volume":"16","author":"Chen X","year":"2024","unstructured":"Chen X, Shu Y, Lin X. Impact of canagliflozin combined with metformin therapy on reducing cardiovascular risk in type 2 diabetes patients. Diabetol Metab Syndr. 2024, 16:199. 10.1186\/s13098-024-01438-1","journal-title":"Diabetol Metab Syndr"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2398","article-title":"Fasting substrate concentrations predict cardiovascular outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)","volume":"45","author":"Ferrannini E","year":"2022","unstructured":"Ferrannini E, Baldi S, Scozzaro T, et al.. Fasting substrate concentrations predict cardiovascular outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS). Diabetes Care. 2022, 45:1893-9. 10.2337\/dc21-2398","journal-title":"Diabetes Care"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195622","article-title":"Predictive factors of renal function decline in patients with type 2 diabetes treated with canagliflozin in the Real-Wecan study","volume":"11","author":"Gorgojo-Martinez JJ","year":"2022","unstructured":"Gorgojo-Martinez JJ, Brito-Sanfiel M, Ant\u00f3n-Bravo T, Gald\u00f3n Sanz-Pastor A, Wong-Cruz J, Gargallo Fern\u00e1ndez MA. Predictive factors of renal function decline in patients with type 2 diabetes treated with canagliflozin in the Real-Wecan study. J Clin Med. 2022, 11:10.3390\/jcm11195622","journal-title":"J Clin Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(23)00727-1","article-title":"Treatment effect of canagliflozin for patients on therapy for heart failure: pooled analysis of the canvas program and credence trial","volume":"81","author":"Jain SS","year":"2023","unstructured":"Jain SS, Yu J, Arnott C, et al.. Treatment effect of canagliflozin for patients on therapy for heart failure: pooled analysis of the canvas program and credence trial. J Am Coll Cardiol. 2023, 81:283. 10.1016\/S0735-1097(23)00727-1","journal-title":"J Am Coll Cardiol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2023.03.025","article-title":"Effect of canagliflozin on heart\u00a0failure hospitalization in diabetes according to\u00a0baseline heart\u00a0failure risk","volume":"11","author":"Khan MS","year":"2023","unstructured":"Khan MS, Segar MW, Usman MS, et al.. Effect of canagliflozin on heart\u00a0failure hospitalization in diabetes according to\u00a0baseline heart\u00a0failure risk. JACC Heart Fail. 2023, 11:825-35. 10.1016\/j.jchf.2023.03.025","journal-title":"JACC Heart Fail"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.08.004","article-title":"Mediators of the effects of canagliflozin on heart\u00a0failure in patients with type 2 diabetes","volume":"8","author":"Li J","year":"2020","unstructured":"Li J, Woodward M, Perkovic V, et al.. Mediators of the effects of canagliflozin on heart\u00a0failure in patients with type 2 diabetes. JACC Heart Fail. 2020, 8:57-66. 10.1016\/j.jchf.2019.08.004","journal-title":"JACC Heart Fail"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14248","article-title":"Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure","volume":"86","author":"de Boer RA","year":"2020","unstructured":"de Boer RA, N\u00fa\u00f1ez J, Kozlovski P, Wang Y, Proot P, Keefe D. Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure. Br J Clin Pharmacol. 2020, 86:1346-56. 10.1111\/bcp.14248","journal-title":"Br J Clin Pharmacol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11010137","article-title":"Effects of SGLT2 inhibitors on atherosclerosis: lessons from cardiovascular clinical outcomes in type 2 diabetic patients and basic researches","volume":"11","author":"Xu J","year":"2021","unstructured":"Xu J, Hirai T, Koya D, Kitada M. Effects of SGLT2 inhibitors on atherosclerosis: lessons from cardiovascular clinical outcomes in type 2 diabetic patients and basic researches. J Clin Med. 2021, 11:10.3390\/jcm11010137","journal-title":"J Clin Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/441386-sodium-glucose-cotransporter-2-sglt2-inhibitors-and-lipid-modulation-in-heart-failure-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T09:12:06Z","timestamp":1766308326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/441386-sodium-glucose-cotransporter-2-sglt2-inhibitors-and-lipid-modulation-in-heart-failure-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,21]]},"references-count":51,"URL":"https:\/\/doi.org\/10.7759\/cureus.99752","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,21]]}}}